NO20054608L - Influensavirusvaksine - Google Patents
InfluensavirusvaksineInfo
- Publication number
- NO20054608L NO20054608L NO20054608A NO20054608A NO20054608L NO 20054608 L NO20054608 L NO 20054608L NO 20054608 A NO20054608 A NO 20054608A NO 20054608 A NO20054608 A NO 20054608A NO 20054608 L NO20054608 L NO 20054608L
- Authority
- NO
- Norway
- Prior art keywords
- influenza vaccine
- influenza virus
- vaccination
- infection
- proteins
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6068—Other bacterial proteins, e.g. OMP
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6075—Viral proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
Sammendrag Foreliggende oppfinnelse tilveiebringer vaksiner mot sykdommer forårsaket av infeksjon med influensavirus og fremgangsmåter for vaksinasjon. Vaksinene omfatter peptider avledet fra M2 og/eller HA-proteiner fra influensavirus konjugert til et bærerprotein.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US45274903P | 2003-03-07 | 2003-03-07 | |
US53069003P | 2003-12-18 | 2003-12-18 | |
PCT/US2004/006978 WO2004080403A2 (en) | 2003-03-07 | 2004-03-05 | Influenza virus vaccine |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20054608D0 NO20054608D0 (no) | 2005-10-06 |
NO20054608L true NO20054608L (no) | 2005-12-07 |
Family
ID=32994463
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20054608A NO20054608L (no) | 2003-03-07 | 2005-10-06 | Influensavirusvaksine |
Country Status (12)
Country | Link |
---|---|
US (1) | US20040223976A1 (no) |
EP (1) | EP1603590A4 (no) |
JP (1) | JP2006519775A (no) |
KR (1) | KR20050114225A (no) |
AU (1) | AU2004220549B2 (no) |
BR (1) | BRPI0407877A (no) |
CA (1) | CA2516919A1 (no) |
MX (1) | MXPA05009580A (no) |
NO (1) | NO20054608L (no) |
NZ (1) | NZ542226A (no) |
RU (1) | RU2005131016A (no) |
WO (1) | WO2004080403A2 (no) |
Families Citing this family (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10144906B4 (de) | 2001-09-12 | 2013-11-28 | Novartis Vaccines And Diagnostics Gmbh | Verfahren zur großtechnischen Herstellung von Impfstoffen |
ES2217967B1 (es) * | 2003-03-31 | 2006-01-01 | Consejo Sup. Investig. Cientificas | Procedimiento de produccion de particulas virales vacias (vlps) del virus inductor de la bursitis infecciosa (ibdv), composiciones necesarias para su puesta a punto y su uso en la elaboracion de vacunas frente al ibdv. |
ES2307345B1 (es) * | 2004-01-21 | 2009-11-13 | Consejo Sup. Investig. Cientificas | Capsidas vacias quimericas del virus causante de la enfermedad de la bursitis infecciosa (ibdv), su procedimiento de obtencion y aplicaciones. |
ES2307346B1 (es) * | 2004-01-21 | 2009-11-13 | Consejo Sup. Investig. Cientificas | Capsidas vacias (vlps(-vp4)) del virus causante de la enfermedad de la bursitis infecciosa (ibdv), su procedimiento de obtencion y aplicaciones. |
WO2006069262A2 (en) * | 2004-12-21 | 2006-06-29 | Vaxinnate Corporation | Compositions of influenza viral proteins and methods of use thereof |
US7572620B2 (en) | 2005-01-11 | 2009-08-11 | Wisconsin Alumni Research Foundation | H3 equine influenza A virus |
US20090047303A1 (en) * | 2005-05-16 | 2009-02-19 | Alan Shaw | Method for improving the immunogenicity of plasmodium antigens |
KR20080027777A (ko) * | 2005-06-01 | 2008-03-28 | 배리에이션 바이오테크놀로지스 아이엔씨. | 펩티드기초 인플루엔자 백신 제제 |
ES2310062B1 (es) * | 2005-07-15 | 2009-11-13 | Bionostra, S.L. | Particulas pseudovirales vacias quimericas derivadas del virus causante de la enfermedad de la bursitis infecciosa (ibdv), procedimiento de obtencion y aplicaciones. |
ATE552846T1 (de) | 2005-12-06 | 2012-04-15 | Yeda Res & Dev | Verbesserter grippeimpfstoff |
GB0613977D0 (en) | 2006-02-07 | 2006-08-23 | Peptcell Ltd | Peptide sequences and compositions |
EP2476432B1 (en) | 2006-03-07 | 2015-08-19 | Vaxinnate Corporation | Compositions that include hemagglutinin, methods of making and methods of use thereof |
WO2007109564A2 (en) * | 2006-03-17 | 2007-09-27 | University Of Massachusetts | Yeast cell particles as oral delivery vehicles for antigens |
US7682619B2 (en) | 2006-04-06 | 2010-03-23 | Cornell Research Foundation, Inc. | Canine influenza virus |
AU2007297801A1 (en) | 2006-07-14 | 2008-03-27 | Sanofi Pasteur Biologics Co. | Construction of recombinant virus vaccines by direct transposon-mediated insertion of foreign immunologic determinants into vector virus proteins |
US8080645B2 (en) | 2007-10-01 | 2011-12-20 | Longhorn Vaccines & Diagnostics Llc | Biological specimen collection/transport compositions and methods |
US8097419B2 (en) | 2006-09-12 | 2012-01-17 | Longhorn Vaccines & Diagnostics Llc | Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009 |
US8084443B2 (en) | 2007-10-01 | 2011-12-27 | Longhorn Vaccines & Diagnostics Llc | Biological specimen collection and transport system and methods of use |
US8652782B2 (en) | 2006-09-12 | 2014-02-18 | Longhorn Vaccines & Diagnostics, Llc | Compositions and methods for detecting, identifying and quantitating mycobacterial-specific nucleic acids |
US9481912B2 (en) | 2006-09-12 | 2016-11-01 | Longhorn Vaccines And Diagnostics, Llc | Compositions and methods for detecting and identifying nucleic acid sequences in biological samples |
AU2007347184A1 (en) | 2006-09-29 | 2008-08-21 | Sanofi Pasteur Biologics Co | Recombinant rhinovirus vectors |
WO2008040098A1 (en) * | 2006-10-04 | 2008-04-10 | Medvet Science Pty Ltd | Immunogenic polypeptides derived from the cleavage loop of precursor hemagglutinin of an influenza virus |
JP2010508860A (ja) * | 2006-11-15 | 2010-03-25 | フォリア バイオテック インコーポレイテッド | パパイヤモザイクウイルスに基づくインフルエンザ用ワクチン |
JP5177451B2 (ja) * | 2006-11-30 | 2013-04-03 | ヴァリエーション バイオテクノロジーズ インコーポレイテッド | インフルエンザワクチン製剤 |
NZ577405A (en) * | 2006-12-06 | 2012-08-31 | Novartis Ag | Vaccines including antigen from four strains of influenza virus |
MX2009013635A (es) * | 2007-06-25 | 2010-05-19 | Univ Tulane | Composiciones que inhiben la influenza y metodos. |
MX2010001284A (es) * | 2007-08-02 | 2010-08-31 | Biondvax Pharmaceuticals Ltd | Vacunas contra la influenza con multiepitope multimerico. |
US11041215B2 (en) | 2007-08-24 | 2021-06-22 | Longhorn Vaccines And Diagnostics, Llc | PCR ready compositions and methods for detecting and identifying nucleic acid sequences |
US9683256B2 (en) | 2007-10-01 | 2017-06-20 | Longhorn Vaccines And Diagnostics, Llc | Biological specimen collection and transport system |
CA2697373C (en) | 2007-08-27 | 2019-05-21 | Longhorn Vaccines & Diagnostics, Llc | Immunogenic compositions and methods |
US10004799B2 (en) | 2007-08-27 | 2018-06-26 | Longhorn Vaccines And Diagnostics, Llc | Composite antigenic sequences and vaccines |
US11041216B2 (en) | 2007-10-01 | 2021-06-22 | Longhorn Vaccines And Diagnostics, Llc | Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples |
US9138470B2 (en) * | 2007-11-02 | 2015-09-22 | The Johns Hopkins University | Multi-component L2 vaccine for prevention of human papilloma virus infection |
US8669046B2 (en) * | 2008-03-12 | 2014-03-11 | Xuguang (Sean) Li | Reagents and methods for detecting influenza virus proteins |
ES2594102T3 (es) | 2008-04-18 | 2016-12-15 | Vaxinnate Corporation | Mutantes por deleción de la flagelina y métodos para su uso |
CA2742288A1 (en) * | 2008-07-30 | 2010-02-04 | Folia Biotech Inc. | Multivalent vaccines based on papaya mosaic virus and uses thereof |
US8658180B2 (en) * | 2008-08-15 | 2014-02-25 | Mark A. Miller | Vaccines against influenza virus |
EP2168987A1 (en) * | 2008-09-22 | 2010-03-31 | Mucosis B.V. | Multifunctional linker protein containing an antibody against hemagglutinin, a conserved influenza antigen and an immunostimulating carrier binding domain |
DK2396032T3 (en) | 2009-02-10 | 2016-12-19 | Seqirus Uk Ltd | Influenza vaccines with reduced amounts of squalene |
US8753623B2 (en) | 2009-04-29 | 2014-06-17 | Runtao He | Influenza vaccine |
WO2011128892A2 (en) * | 2010-04-12 | 2011-10-20 | Protea Vaccine Technologies Ltd. | Modified forms of pneumococcal surface immunogenic protein b (psipb) |
ES2687706T3 (es) | 2010-06-17 | 2018-10-26 | Trellis Bioscience, Llc | Anticuerpos útiles en la inmunización pasiva contra la gripe |
CN103517713A (zh) | 2011-02-22 | 2014-01-15 | 彼昂德瓦克斯医药有限公司 | 在改善的季节性和大流行性流感疫苗中的多聚体多表位多肽 |
WO2013086052A2 (en) | 2011-12-05 | 2013-06-13 | Trellis Bioscience, Llc | Antibodies useful in passive influenza immunization |
WO2013112916A1 (en) | 2012-01-26 | 2013-08-01 | Longhorn Vaccines And Diagnostics, Llc | Composite antigenic sequences and vaccines |
US8932598B2 (en) | 2012-08-28 | 2015-01-13 | Vaxinnate Corporation | Fusion proteins and methods of use |
AU2014236508A1 (en) | 2013-03-14 | 2015-09-17 | Contrafect Corporation | Composition and methods based on neutralizing antibodies delivered intranasally for enhanced therapeutic efficacy |
WO2015120097A2 (en) | 2014-02-04 | 2015-08-13 | Contrafect Corporation | Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof |
US10639370B2 (en) | 2014-02-04 | 2020-05-05 | Contrafect Corporation | Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof |
WO2016183292A1 (en) | 2015-05-14 | 2016-11-17 | Longhorn Vaccines And Diagnostics, Llc | Rapid methods for the extraction of nucleic acids from biological samples |
EP3568157A4 (en) * | 2017-01-13 | 2021-01-06 | National Research Council of Canada | METHOD FOR OPTIMIZING THE PEPTIDE IMMUNO-EPITOP BY GLYCOSYLATION, OPTIMIZED PEPTIDE THEREOF AND ITS USE FOR CONJUGATE VACCINES |
WO2018237115A2 (en) | 2017-06-23 | 2018-12-27 | Pathovax Llc | CHIMERIC VIRUS-LIKE PARTICLES AND THEIR USES AS SPECIFIC REDIRECTORS OF ANTIGENS OF IMMUNE RESPONSES |
WO2020139978A1 (en) | 2018-12-27 | 2020-07-02 | Verimmune Llc | Conjugated virus-like particles and uses thereof as anti-tumor immune redirectors |
KR102393872B1 (ko) * | 2019-08-28 | 2022-05-04 | 엠브릭스 주식회사 | 바이러스 외피를 손상시키는 m2 단백질 유래 항바이러스 펩타이드 및 그의 용도 |
JP2022551918A (ja) * | 2019-10-09 | 2022-12-14 | エドワード フリッチュ, | マルチドメインタンパク質ワクチン |
WO2022020545A2 (en) * | 2020-07-22 | 2022-01-27 | Texas Tech University System | Coronavirus vaccine |
AU2021364548A1 (en) | 2020-10-19 | 2023-06-08 | Verimmune Inc. | Virus-inspired compositions and methods of redirecting preexisting immune responses using the same for treatment of cancer |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4271147A (en) * | 1980-01-10 | 1981-06-02 | Behringwerke Aktiengesellschaft | Process for the isolation of membrane proteins from Neisseria meningitidis and vaccines containing same |
IL61904A (en) * | 1981-01-13 | 1985-07-31 | Yeda Res & Dev | Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same |
US4695624A (en) * | 1984-05-10 | 1987-09-22 | Merck & Co., Inc. | Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency |
US4707543A (en) * | 1985-09-17 | 1987-11-17 | The United States Of America As Represented By The Secretary Of The Army | Process for the preparation of detoxified polysaccharide-outer membrane protein complexes, and their use as antibacterial vaccines |
IL98845A0 (en) * | 1990-07-19 | 1992-07-15 | Merck & Co Inc | Coconjugate vaccines comprising immunogenic protein,hiv related peptides,and anionic moieties,their preparation and pharmaceutical compositions containing them |
US5612037A (en) * | 1994-07-26 | 1997-03-18 | Connaught Laboratories, Inc. | Influenza virus subunit conjugates |
US5494808A (en) * | 1994-09-15 | 1996-02-27 | Merck & Co., Inc. | Defined medium OMPC fermentation process |
US5840306A (en) * | 1995-03-22 | 1998-11-24 | Merck & Co., Inc. | DNA encoding human papillomavirus type 18 |
US5820870A (en) * | 1995-03-22 | 1998-10-13 | Merck & Co., Inc. | Recombinant human papillomavirus type 18 vaccine |
IL117591A0 (en) * | 1995-03-30 | 1996-07-23 | Merck & Co Inc | Synthetic DNA encoding human papillomavirus type 11 L1 protein |
US6169175B1 (en) * | 1997-08-06 | 2001-01-02 | Centers For Disease Control And Prevention | Preparation and use of recombinant influenza A virus M2 construct vaccines |
CA2407897A1 (en) * | 2000-05-05 | 2001-11-15 | Cytos Biotechnology Ag | Molecular antigen arrays and vaccines |
WO2002026252A1 (fr) * | 2000-08-10 | 2002-04-04 | Tsinghua University | Vaccin contre le virus de la grippe et son procede de preparation |
US20030175863A1 (en) * | 2001-08-15 | 2003-09-18 | Birkett Ashley J. | Influenza immunogen and vaccine |
-
2004
- 2004-03-05 US US10/794,646 patent/US20040223976A1/en not_active Abandoned
- 2004-03-05 AU AU2004220549A patent/AU2004220549B2/en not_active Ceased
- 2004-03-05 RU RU2005131016/15A patent/RU2005131016A/ru not_active Application Discontinuation
- 2004-03-05 NZ NZ542226A patent/NZ542226A/en unknown
- 2004-03-05 MX MXPA05009580A patent/MXPA05009580A/es unknown
- 2004-03-05 KR KR1020057016723A patent/KR20050114225A/ko not_active Application Discontinuation
- 2004-03-05 BR BRPI0407877-2A patent/BRPI0407877A/pt not_active IP Right Cessation
- 2004-03-05 CA CA002516919A patent/CA2516919A1/en not_active Abandoned
- 2004-03-05 WO PCT/US2004/006978 patent/WO2004080403A2/en active IP Right Grant
- 2004-03-05 EP EP04718139A patent/EP1603590A4/en not_active Withdrawn
- 2004-03-05 JP JP2006501224A patent/JP2006519775A/ja not_active Withdrawn
-
2005
- 2005-10-06 NO NO20054608A patent/NO20054608L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
WO2004080403A2 (en) | 2004-09-23 |
AU2004220549A1 (en) | 2004-09-23 |
CA2516919A1 (en) | 2004-09-23 |
JP2006519775A (ja) | 2006-08-31 |
BRPI0407877A (pt) | 2006-03-01 |
NZ542226A (en) | 2008-08-29 |
EP1603590A4 (en) | 2008-08-27 |
EP1603590A2 (en) | 2005-12-14 |
KR20050114225A (ko) | 2005-12-05 |
NO20054608D0 (no) | 2005-10-06 |
RU2005131016A (ru) | 2006-06-10 |
MXPA05009580A (es) | 2005-10-19 |
WO2004080403A3 (en) | 2005-06-09 |
AU2004220549B2 (en) | 2007-07-05 |
US20040223976A1 (en) | 2004-11-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20054608L (no) | Influensavirusvaksine | |
ES2741729T3 (es) | Vectores y construcciones de liberación de antígenos de virus de la gripe | |
EA200900784A1 (ru) | Вакцины, включающие антиген из четырех штаммов вируса гриппа | |
FR2827605B1 (fr) | Nouveaux peptides derives de la proteine g du vrs et leur utilisation dans un vaccin | |
ATE331530T1 (de) | Proteasom-influenzavirus-impfstoffzusammensetzu g | |
CY1111378T1 (el) | Προερχομενα απο κυτταρα ιικα εμβολια με χαμηλα επιπεδα υπολειμματικου κυτταρικου dna | |
ATE426412T1 (de) | Adjuvante influenza-vakzine | |
MY126588A (en) | Intranasal influenza virus vaccine | |
EA200801756A1 (ru) | Противогриппозные вакцины, содержащие гемагглютинин и белки матрикса | |
MX342639B (es) | Virus de la influenza recombinantes de alta titulacion para vacunas y terapia genica. | |
DK1881845T3 (da) | Nipah-virusvacciner | |
WO2007095318A3 (en) | Influenza antigens, vaccine compositions, and related methods | |
DK1618889T3 (da) | Influenzavaccine | |
SG156652A1 (en) | Yeast-based therapeutic for chronic hepatitis c infection | |
BRPI0707779B8 (pt) | antígeno isolado, composição de vacina e método para produção de uma proteína antígeno | |
DK1951300T3 (da) | Ændring af Th1/Th2-balancen i split-influenzavacciner med adjuvanser | |
EA201391200A1 (ru) | Способы и композиции для вакцинации от staphylococcus aureus | |
WO2006071896A3 (en) | Epitope-based sars vaccine | |
EA201690115A1 (ru) | Комбинированные иммуногенные композиции | |
ATE508185T1 (de) | Virosomenpartikel mit antigenen aus influenzavirus und hepatitis-b-virus | |
ATE507286T1 (de) | Immunisierung von fischen gegen virusinfektion | |
WO2009074861A3 (en) | Improved vaccine | |
GB2429711A (en) | Heart and skeletal muscle inflammation (HSMI) virus | |
CY1107560T1 (el) | Ζωντανα εξασθενημενα βακτηρια για χρηση σε εμβολιο | |
WO2006062637A3 (en) | Influenza vaccination |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |